In prostate cancer, the PROfound and TALAPRO-2 trials demonstrated that PARP inhibitors significantly improve outcomes in patients with metastatic castration-resistant disease and homologous recombination repair alterations, with the most pronounced benefit observed in those with BRCA1/2 mutations (17, 38). The gene discussed is BRCA1; the disease is prostate carcinoma.